Clinical Trial ProgressThe progress on the dose escalation portion of the Phase 1 trial for LNCB74 is viewed as a positive signal of safety with no dose-limiting toxicities noted.
Preclinical ResultsNextCure's LNCB74 has demonstrated superior efficacy in preclinical results compared to similar competitors, indicating potential for better outcomes.
Strategic PartnershipNextCure entered into a strategic partnership with Chinese pharma company Simcere to develop and commercialize SIM0505, a novel antibody-drug conjugate (ADC) for the treatment of solid tumors.